|
Market Closed -
Nasdaq
16:00:00 2026-09-29 EDT
|
5-day change | 1st Jan Change | ||
| 4.400 USD | +6.54% |
|
-1.79% | -62.23% |
| 08-13 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-13 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 438M | - | - | - | ||
| 48.85B | |||||
| 44.28B | |||||
| 43.83B | - | - | - | - | - |
| 41.53B | |||||
| 30.13B |
Select your edition
All financial news and data tailored to specific country editions
